ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 156 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2017. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $880,000 | -8.4% | 13,855 | 0.0% | 0.05% | -15.0% |
| Q1 2019 | $961,000 | +29.5% | 13,855 | -18.8% | 0.06% | +5.3% |
| Q4 2018 | $742,000 | -43.0% | 17,055 | 0.0% | 0.06% | -20.8% |
| Q3 2018 | $1,302,000 | -13.0% | 17,055 | -12.3% | 0.07% | -15.3% |
| Q2 2018 | $1,496,000 | +7.6% | 19,455 | -28.6% | 0.08% | +18.1% |
| Q1 2018 | $1,390,000 | +10.0% | 27,255 | 0.0% | 0.07% | +24.1% |
| Q4 2017 | $1,264,000 | -39.1% | 27,255 | -30.1% | 0.06% | -37.0% |
| Q3 2017 | $2,076,000 | -14.3% | 38,975 | 0.0% | 0.09% | -10.7% |
| Q2 2017 | $2,421,000 | -8.4% | 38,975 | 0.0% | 0.10% | -23.1% |
| Q1 2017 | $2,642,000 | -8.9% | 38,975 | -5.5% | 0.13% | -1.5% |
| Q4 2016 | $2,900,000 | -37.1% | 41,250 | -36.5% | 0.14% | -3.5% |
| Q3 2016 | $4,611,000 | +3.0% | 65,000 | -29.0% | 0.14% | -23.0% |
| Q2 2016 | $4,475,000 | – | 91,500 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |